Skip to Content

Pentacel Approval History

Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Development History and FDA Approval Process for Pentacel

Jun 23, 2008Approval U.S. FDA Licenses Sanofi Pasteur's New Pediatric CombinationVaccine, Pentacel
Jan 25, 2007FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine
Sep 26, 2005FDA Accepts for Filing a License Application for New Pediatric Combination Vaccine, Pentacel

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.